tiprankstipranks
Palvella Therapeutics (DE:PI6)
FRANKFURT:PI6
Germany Market
PI6
Palvella Therapeutics
RESEARCH TOOLSreports

Palvella Therapeutics (PI6) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

PI6 Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Palvella
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PI6 Stock 12 Month Forecast

Average Price Target

€200.34
▲(59.00% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is €200.34 with a high forecast of €231.96 and a low forecast of €176.12. The average price target represents a 59.00% change from the last price of €126.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"45":"€45","232":"€232","91.75":"€91.8","138.5":"€138.5","185.25":"€185.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":231.9563709,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€231.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200.34157664399999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€200.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":176.11502235,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€176.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[45,91.75,138.5,185.25,232],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130,137.84279776153846,145.68559552307693,153.5283932846154,161.37119104615385,169.21398880769232,177.05678656923078,184.89958433076924,192.7423820923077,200.58517985384617,208.42797761538463,216.2707753769231,224.11357313846153,{"y":231.9563709,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130,135.41089051107693,140.82178102215386,146.23267153323076,151.64356204430769,157.05445255538461,162.46534306646154,167.87623357753847,173.28712408861537,178.6980145996923,184.10890511076923,189.51979562184613,194.93068613292309,{"y":200.34157664399999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130,133.54730941153846,137.09461882307693,140.6419282346154,144.18923764615386,147.73654705769232,151.28385646923078,154.83116588076922,158.37847529230768,161.92578470384615,165.4730941153846,169.02040352692308,172.56771293846154,{"y":176.11502235,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€231.96Average Price Target€200.34Lowest Price Target€176.12
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on DE:PI6
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
€206.18
Buy
63.64%
Upside
Reiterated
09/10/26
Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA)
LifeSci Capital Analyst forecast on DE:PI6
Sam Slutsky
LifeSci Capital
LifeSci Capital
€193.3→€202.75
Buy
60.91%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DE:PI6
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€231.96
Buy
84.09%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)
Oppenheimer Analyst forecast on DE:PI6
Trevor Allred
Oppenheimer
Oppenheimer
€180.41
Buy
43.18%
Upside
Reiterated
08/05/26
Oppenheimer Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
Canaccord Genuity Analyst forecast on DE:PI6
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€195.02→€199.31
Buy
58.18%
Upside
Reiterated
08/05/26
Palvella Therapeutics price target raised to $232 from $227 at CanaccordPalvella Therapeutics price target raised to $232 from $227 at Canaccord
Truist Financial Analyst forecast on DE:PI6
Danielle Brill
Truist Financial
Truist Financial
€180.41→€177.83
Buy
41.14%
Upside
Reiterated
08/05/26
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
TD Cowen Analyst forecast on DE:PI6
Ritu Baral
TD Cowen
TD Cowen
€229.38
Buy
82.05%
Upside
Reiterated
08/04/26
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
BTIG Analyst forecast on DE:PI6
Jeet Mukherjee
BTIG
BTIG
€184.71
Buy
46.59%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Henry Schein (NASDAQ: HSIC), OrthoPediatrics (NASDAQ: KIDS) and Palvella Therapeutics (NASDAQ: PVLA)
Stifel Nicolaus Analyst forecast on DE:PI6
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
€214.77
Buy
70.46%
Upside
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)
Craig-Hallum Analyst forecast on DE:PI6
Albert Lowe
Craig-Hallum
Craig-Hallum
€176.12
Buy
39.77%
Upside
Reiterated
06/22/26
Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
Chardan Capital Analyst forecast on DE:PI6
Geulah Livshits
Chardan Capital
Chardan Capital
€206.18
Buy
63.64%
Upside
Reiterated
05/20/26
Chardan Capital Keeps Their Buy Rating on Palvella Therapeutics (PVLA)
Stephens Analyst forecast on DE:PI6
Sudan Loganathan
Stephens
Stephens
€189
Buy
50.00%
Upside
Initiated
05/11/26
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
Clear Street Analyst forecast on DE:PI6
Kaveri Pohlman
Clear Street
Clear Street
€171.82→€189
Buy
50.00%
Upside
Reiterated
03/02/26
Palvella Therapeutics (PVLA) Receives a Buy from Clear Street
JonesTrading Analyst forecast on DE:PI6
Catherine Novack
JonesTrading
JonesTrading
€122.85→€179.55
Buy
42.50%
Upside
Reiterated
02/24/26
Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch
Cantor Fitzgerald Analyst forecast on DE:PI6
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
€171.82→€180.41
Buy
43.18%
Upside
Reiterated
12/15/25
Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on DE:PI6
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
€206.18
Buy
63.64%
Upside
Reiterated
09/10/26
Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA)
LifeSci Capital Analyst forecast on DE:PI6
Sam Slutsky
LifeSci Capital
LifeSci Capital
€193.3→€202.75
Buy
60.91%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DE:PI6
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€231.96
Buy
84.09%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)
Oppenheimer Analyst forecast on DE:PI6
Trevor Allred
Oppenheimer
Oppenheimer
€180.41
Buy
43.18%
Upside
Reiterated
08/05/26
Oppenheimer Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
Canaccord Genuity Analyst forecast on DE:PI6
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€195.02→€199.31
Buy
58.18%
Upside
Reiterated
08/05/26
Palvella Therapeutics price target raised to $232 from $227 at CanaccordPalvella Therapeutics price target raised to $232 from $227 at Canaccord
Truist Financial Analyst forecast on DE:PI6
Danielle Brill
Truist Financial
Truist Financial
€180.41→€177.83
Buy
41.14%
Upside
Reiterated
08/05/26
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
TD Cowen Analyst forecast on DE:PI6
Ritu Baral
TD Cowen
TD Cowen
€229.38
Buy
82.05%
Upside
Reiterated
08/04/26
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
BTIG Analyst forecast on DE:PI6
Jeet Mukherjee
BTIG
BTIG
€184.71
Buy
46.59%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Henry Schein (NASDAQ: HSIC), OrthoPediatrics (NASDAQ: KIDS) and Palvella Therapeutics (NASDAQ: PVLA)
Stifel Nicolaus Analyst forecast on DE:PI6
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
€214.77
Buy
70.46%
Upside
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)
Craig-Hallum Analyst forecast on DE:PI6
Albert Lowe
Craig-Hallum
Craig-Hallum
€176.12
Buy
39.77%
Upside
Reiterated
06/22/26
Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
Chardan Capital Analyst forecast on DE:PI6
Geulah Livshits
Chardan Capital
Chardan Capital
€206.18
Buy
63.64%
Upside
Reiterated
05/20/26
Chardan Capital Keeps Their Buy Rating on Palvella Therapeutics (PVLA)
Stephens Analyst forecast on DE:PI6
Sudan Loganathan
Stephens
Stephens
€189
Buy
50.00%
Upside
Initiated
05/11/26
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
Clear Street Analyst forecast on DE:PI6
Kaveri Pohlman
Clear Street
Clear Street
€171.82→€189
Buy
50.00%
Upside
Reiterated
03/02/26
Palvella Therapeutics (PVLA) Receives a Buy from Clear Street
JonesTrading Analyst forecast on DE:PI6
Catherine Novack
JonesTrading
JonesTrading
€122.85→€179.55
Buy
42.50%
Upside
Reiterated
02/24/26
Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch
Cantor Fitzgerald Analyst forecast on DE:PI6
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
€171.82→€180.41
Buy
43.18%
Upside
Reiterated
12/15/25
Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
AXGNAxoGen
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

3 Months
Andrew FeinH.C. Wainwright
Success Rate
15/17 ratings generated profit
88%
Average Return
+54.55%
Copying Andrew Fein's trades and holding each position for 3 Months would result in 88.24% of your transactions generating a profit, with an average return of +54.55% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
9/9 ratings generated profit
100%
Average Return
+173.37%
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +173.37% per trade.
2 Years
Geulah LivshitsChardan Capital
Success Rate
9/9 ratings generated profit
100%
Average Return
+202.07%
Copying Geulah Livshits's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +202.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PI6 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
32
28
28
17
12
Buy
2
1
2
5
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
34
29
30
22
17
In the current month, PI6 has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PI6 average Analyst price target in the past 3 months is 200.34.
Each month's total comprises the sum of three months' worth of ratings.

PI6 Financial Forecast

PI6 Earnings Forecast

Next quarter’s earnings estimate for PI6 is -€1.55 with a range of -€2.00 to -€0.91. The previous quarter’s EPS was -€1.32. PI6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PI6 has Performed in-line its overall industry.
Next quarter’s earnings estimate for PI6 is -€1.55 with a range of -€2.00 to -€0.91. The previous quarter’s EPS was -€1.32. PI6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PI6 has Performed in-line its overall industry.

PI6 Sales Forecast

Next quarter’s sales forecast for PI6 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. PI6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PI6 has Performed in-line its overall industry.
Next quarter’s sales forecast for PI6 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. PI6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PI6 has Performed in-line its overall industry.

PI6 Stock Forecast FAQ

What is DE:PI6’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is 200.34.
    What is DE:PI6’s upside potential, based on the analysts’ average price target?
    Palvella Therapeutics has 59.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Palvella Therapeutics a Buy, Sell or Hold?
          Palvella Therapeutics has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Palvella Therapeutics’s share price target?
            The average share price target for Palvella Therapeutics is 200.34. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €231.96 ,and the lowest forecast is €176.12. The average share price target represents 59.00% Increase from the current price of €126.
              What do analysts say about Palvella Therapeutics?
              Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Palvella Therapeutics?
                To buy shares of DE:PI6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.